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The  issue  of affordability  of  health  care  services  remains  high  on  the (health)  policy  agenda.
Determining  whether  health  care  services  are  affordable  is complex,  however,  as the con-
cept  ‘affordability’  is inherently  normative.  With  a focus  on  measuring  affordability  in low-
and  middle-income  countries,  we  discuss  different  methods  used  to operationalize  thiseywords:
ffordability
omparison
ethodology
edicines
concept.  Using  the example  of medicine  purchases  in Indonesia,  we  show  the  choice  of
method and  threshold  to  have  a signiﬁcant  impact  on  outcomes.  We  argue  it is impor-
tant  to  further  standardize  methods  and  appropriate  threshold  use  in applied  research  to
increase  comparability  of  results  and  to facilitate  sound  assessments  of affordability.
© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.
hresholds
. Introduction
Issues of affordability appear to be at the center of health
are discussions and decisions. Politicians and health care
olicy makers alike, in both high- and low- and middle-
ncome countries (LMICs), see themselves confronted with
he challenge of ensuring and, where possible, increasing
ccess to health care services of sufﬁcient quality for all
hose in need while at the same time containing (public)
ealth care expenditures. This challenge raises numer-
us important questions and dilemmas. Some have even
rgued that these goals form an ‘inconsistent triad’, i.e.
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Open access undethat they can never be completely fulﬁlled simultaneously
[1]. Still, policy makers may  attempt to strike an optimal
balance in reaching these goals.
An important issue in that context is that of afford-
ability. In both high- as well as low- and middle-income
countries policy makers struggle with questions regarding
the payments people should be able to make out-of-pocket
(OOP) on health care or through copayments in some
form (affordability at micro level) and the sustainability of
public funding of the health care sector raised through pre-
miums  or taxes (affordability at macro level) [2,3]. Because
in LMICs the large majority of the population does not
have health insurance [4], OOP payments are an important
source of health care ﬁnancing. Much of these OOP pay-
ments are on medicines, as in LMICs medicine expenditures
often constitute a large portion of total health expendi-
tures [2,3,5–7]. Indeed, as in LMICs the availability of ‘free’
quality assured medicines in the public sector often is low,
people are forced to buy their medication in the private
sector where prices are commonly high [3]. This imme-
diately stresses the issue of affordability. By deﬁnition,
an average individual in a low- or middle-income coun-
try has only a limited amount of resources with which all
basic needs (food, housing, etc.) need to be fulﬁlled. The
r CC BY-NC-ND license.
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amount of money people thus can spend on health care, or
more speciﬁcally medicines, therefore is limited. If prices
of these medicines exceed the budget, people may  forego
procurement of essential drugs, go into debt or forego other
essential purchases [3,7,8]. This stresses the gravity of the
topic of affordability, which is also emphasized in several
international treaties in which the access to health care is
established as a right. This therefore must imply that OOP
payments should be, somehow, ‘affordable’ [9].
In this paper, we will highlight the issue of deﬁning and
measuring affordability. We  focus on affordability of health
care, and medicines in particular, at the micro level in
LMICs. We  will emphasize how different methods to quan-
tify affordability can have their speciﬁc limitations and lead
to different results. Within methods, a further source of
variation in affordability is setting a speciﬁc threshold for
affordability. We  will address these issues generally and
will use the example of Indonesia to illustrate our point.
The paper is structured as follows. After a concise intro-
duction of affordability, we ﬁrst discuss several empirical
studies of affordability in health care. We  will highlight the
differences in methods used and differences in operational-
isations of similar methods. Next, we use an example of
hypothetical medicine procurements in Indonesia to show
how these different methods and their operationalisations
inﬂuence the outcome of affordability measurement. The
paper concludes by arguing that further standardization
of methods used in this area will allow better comparison
of results across studies and may  stimulate further debate
on when speciﬁc health care interventions can be deemed
affordable or should be deemed unaffordable.
2. On affordability of health care and medicines
Affordability is an important, yet hard to deﬁne let alone
operationalize concept. This has much to do with the fact
that, by deﬁnition, deﬁning affordability is a normative
issue [10]. Indeed, it requires deﬁning when we  consider
something to be too expensive for someone. One (extreme)
answer could be that a good is unaffordable when the
price of that good exceeds the total budget a person can
attract. That however disregards all other spending (even
at subsistence level) that a person needs to do. Another
viewpoint could be that a person should at least be able to
fulﬁll other basic needs after having purchased the good.
From such a viewpoint a good is unaffordable if the indi-
vidual, after the purchase, does not have enough resources
left to fulﬁll her basic needs, i.e. falls below a poverty line.
A difﬁcult subsequent issue relates to the level at which
the poverty line is set. A ﬁnal alternative would be to link
the price to the income of the individual and require it not
to exceed some percentage of total income. Again here, a
difﬁcult next question is what this percentage should be
exactly. When is it too expensive, that is, unaffordable?
Unsurprisingly therefore, scholars in various ﬁelds, work-
ing on deﬁning and measuring affordability, have indeed
acknowledged the normativity of the affordability concept
[10–16]. Moreover, it need not surprise that in applied work
different concepts are used to calculate affordability in dif-
ferent areas such as housing [13,17,18], education [19,20],
transportation [21,22] and utilities [14,23]. Policy 112 (2013) 45– 52
In many studies investigating (un)affordability of goods
and services, the focus is on estimating a proportion of the
population for which a particular good or service is unaf-
fordable. In general, this requires three different sources
of information: (i) the price of a commodity or service; (ii)
income(s), and (iii) some measure of unacceptable burden
[16,24]. The latter shall be labeled as ‘threshold’ henceforth.
Whereas the ﬁrst two parameters are to a large extent a
matter of obtaining appropriate data (which can be chal-
lenging as well), setting the threshold essentially involves a
normative choice, but one that inﬂuences the outcomes sig-
niﬁcantly. It thus lies at the heart of the ‘vagueness’ [10] of
the affordability concept and appears an issue that deserves
more debate and, if possible, further standardization.
In calculating affordability, the two most applied
methodologies relate to the concepts of impoverishment
and catastrophic spending as developed and applied by
renowned health economists Wagstaff and van Doorslaer
[25,26]. Methods based on the impoverishment concept
calculate the proportion of the population that, after spend-
ing on a good/service, drops below a relevant poverty line.
Thus, the impoverishment method works from the premise
that there is an absolute minimum level of income peo-
ple require for basic necessities. Implicitly, some poverty
line is used as a threshold, therefore. The other method,
catastrophic spending, calculates the proportion of the
population that would spend more than X percent of their
income to pay for a good/service. This method thus sets
a threshold in terms of a forgone proportion of income.
The underlying idea is that if a household spends a larger
fraction of its income than the speciﬁed percentage on a
particular good or service, it will have to scale back its
consumption in other areas to an inappropriate extent. A
common way  of using these methods is to retrospectively
assess how many people actually experienced impover-
ishment or catastrophic payments due to expenditures
(on health care) [25,26]. The methods can also be used to
prospectively calculate the proportion of the population for
which the good would be unaffordable if it needed to be
purchased. This provides insight in the proportion of the
population at risk of facing either impoverishment or cat-
astrophic payments if the good or service would need to be
bought [7].
Because affordability in the impoverishment and cat-
astrophic payment methods is calculated in relation to
the actual incomes in the population, they automatically
take into account the income distribution. An alterna-
tive methodology recently developed by the World Health
Organization (WHO) and Health Action International (HAI)
measuring affordability does not use this distribution.
This straightforward method expresses the affordability of
medicines in the number of days’ wages the lowest paid
unskilled government worker (LPGW) needs to spend to
procure a course of treatment of a particular medicine
[3,27]. WHO/HAI do not pose a threshold with the LPGW-
method and leave the judgment regarding whether some
medicine is deemed affordable to local policymakers who
more easily can position the LPGW wage in relation to the
average income (and its distribution) of the local popu-
lation. Each of these three methods has own  limitations,
which will be brieﬂy discussed in the next section.
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. Different methods, different limitations
The retrospective or prospective application of the
mpoverishment method captures the people that were or
ould be pushed below some relevant poverty line due to
he procurement of health care or medicines (the impov-
rishment rate) and, as such, immediately shows which
roportion of the population was impoverished or is poten-
ially at risk of becoming impoverished. The method’s main
eakness is that it normally works from a rather extreme
hreshold. If used naively the method also ignores those
lready below the poverty line, which obviously can be
asily corrected by including those living below that line
nyhow [7]. Furthermore, for those people who are not
ushed below a (commonly low) poverty line, but nonethe-
ess experience a strong income drop, the relevant good is
ot deemed unaffordable, which may  be considered debat-
ble. Elevating the poverty line to a higher level could help,
f course, but at the same time stretches the concept of
overty. A clear consensus on what the poverty line is or
hould be, does not exist. This is reﬂected in the range
f values used in applied literature [2,3,7,28–31]. Hence,
he more fundamental question is what poverty actually
ntails.
The main weakness of the catastrophic approach is that
he rich, who can easily spend more than X percent of their
ncome on medicines without suffering any hardship, are
ncluded in the estimates of ‘unaffordability’, while the very
oor, for whom spending less than X percent may  already
e difﬁcult (due to strict budget constraints and perhaps
eing pushed under a poverty line) are not. Hence, the
ethod may  not fully capture those individuals in estimat-
ng affordability, for which affordability, loosely deﬁned, is
ctually a problem. The main question remaining in the
atastrophic payment approach hence concerns the level
f spending to be deemed affordable, and whether such a
evel might differ for high and low incomes.
The main advantage of the LPGW method is its simplic-
ty and straightforwardness, both in terms of its application
nd how, on a local level, many people may  be able to
osition themselves in relation to this LPGW. However, in
ts simplicity also lies its main weakness, i.e. knowing the
umber of daily wages the LPGW needs to pay for a course
f medicines does not provide clear information on what
his means for the population as a whole. Furthermore, its
ink to the concept off affordability also is less clear as is
etting a threshold for the number of days the LPGW needs
o work for medicines.
A shortcoming the three methods have in common is
hat comparing their results across countries and time is
ot possible when different thresholds (let alone methods)
re used. The choice of methods and their operational-
zation thus requires attention. This is highlighted in the
ext section, where we focus on the most commonly used
mpoverishment and catastrophic payment methods.
. Practical applications of the methodsAs the impoverishment and catastrophic payment
ethods deﬁne affordability in different ways, they can
ield different answers to the question whether some Policy 112 (2013) 45– 52 47
medicine is affordable to speciﬁc populations. Moreover,
within methods the variation in answers can also be rather
large when different poverty lines are used within the
impoverishment method or when different percentages
are used in operationalizing the catastrophic payment
method. The next paragraph will substantiate this point by
summarizing the ﬁndings of different empirical studies. (It
needs noting that different data sources can also affect the
outcomes.)
Several studies have been conducted applying these
methods in the health care sector. In investigating the effect
of OOP payments in health care on poverty estimates in 11
LMICs, van Doorslaer and colleagues used the World Bank’s
absolute poverty lines of US$1.08 and US$2.15. Using
household data and actual expenditures they retrospec-
tively show 78 million people to have dropped below the
US$1.08 poverty line when their payments for health care
were subtracted from their incomes [2]. Niëns et al. worked
with the World Bank’s 2005 poverty line of US$1.25 and
US$2.00 [32,33] to calculate medicine affordability for four
essential medicines across 16 LMICs with a total popula-
tion over 775 million. Applying the methods prospectively,
their results for example indicate that, at the US1.25 PL,
the lowest cost medicine (salbutamol inhaler), would be
unaffordable for 140 million people in these countries [7].
Finally, in Mexico, Knaul et al. applied a US$1.00 thresh-
old, reporting 3.8% of families to suffer from impoverishing
health care expenditures each trimester [34].
Besides these poverty lines other thresholds have been
used as well within the impoverishment method. In Viet-
nam, Wagstaff and van Doorslaer applied both a food-based
poverty line, based on the cost of reaching an intake
of 2100 calories per day, as well as a poverty line that
captured spending requirements on food and non-food
items [26]. Furthermore, in Thailand several studies used
the ofﬁcial national poverty line adapted to the speciﬁc
province [29,31]. These studies showed that households
using private inpatient services had a higher incidence
of impoverishment [31] and that impoverishment rates
decreased after the implementation of a policy broadening
insurance coverage [29].
For catastrophic spending methods in the realm of
health care, Xu et al. retrospectively applied a thresh-
old of “40% of income remaining after subsistence needs
have been met” [28]. They found that a 1% increase in
the total proportion of total health expenditures provided
by out-of-pocket payments resulted in a 2.2% increase
in households facing catastrophic expenditures. Although
Sun et al. also used the 40% of non-food expenditure thresh-
old when retrospectively calculating the affordability of
total health care in rural China, using sensitivity analy-
ses with thresholds of 20%, 30%, 50% and 60%, they found
catastrophic payments to decrease by 34.77% comparing
the 20% and 60% thresholds [30]. Using similar thresh-
olds (20%, 30%, 40% and 60%) in a study in Burkina Faso,
Su et al. found catastrophic health care expenditure to
decrease by 57.26% comparing the 20% and 60% thresholds
[35]. Niëns et al. prospectively applied a 5% threshold of
daily income when calculating the affordability of an anti-
diabetic drug, glibenclamide, and found 65.9% and 78.6% of
the Indonesian and Indian populations respectively to be
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Table 1
Affordability studies in Health care.
Authors Country Topic Method:
Impov./Cat.
Income measure Poverty Line used Results
van Doorslaer et al. [2] 11 LMICs Total health care
costs
Impov. (R) HH-surveys - US$1.08 & US$2.15 78 million people dropped below US$1.08 due to HC costs
Niëns  et al. [7] 16 LMICs Medicine
affordability
Impov. (P) Estimates from
aggregated World
Bank data
- US$1.25 & US$2.00 At US$1.25 salbutamol inhaler is unaffordable for 140 mln.
people on pop. of 775 mln.
Knaul  et al. [34] Mexico. Total health care
costs
Impov. & Cat. (R) Mexican Survey of
HH income and
exp.
- US$1.00 – 30% of total
income minus food exp.
3.8% of pop. impoverished (most in low-income
quintiles)/cat. payments over total income distribution
Wagstaf and van
Doorslaer [26]
Vietnam. Impov. & Cat. (R) Total HH cons.,
gross of OOP
payment for health
services.
-  FPL based on cost of
reaching 2100 calories per
day -PL capturing spending
on food and non-food
items.
Between ’93 and ’98: – Impov. FPL dropped from 4.4% to
3.4%. For the PL impov. increased: 0.4% to 0.5% – Cat.
payments more concentrated amongst the poor but
decreased in time period
Limwattananon et al.
[31]
Thailand. Total health care
costs
Impov. & Cat. (R) Total HH- exp. - Ofﬁcial national PL
adapted to regions - 10% of
total cons.; food included.
Cat. payments mostly occur for inpatient services (31.0% in
’00 and 14.6% in ’04). For outpatient services they
decreased by approx. 33% (12.0% in ’00 to 8.3% in ’04)
Somkotra et al. [29] Thailand. Total health care
costs
Impov. & Cat. (R) Total HH-cons. - Province-speciﬁc PL. –
5%/10%/15% of total cons. -
25%/30% of non-food cons.
Introduction UC in ’00→ Cat. Payments decreased by
24.48% between ’00 and ’04. Impov. Decreased from 1.23%
to  0.58% in same time period.
Xu  et al. [28] 59 countries. Cat. (R) HH-surveys. - 40% of income minus
average food exp.
1% increase in proportion total HC exp. Paid for by OOP
payments → 2.2% increase in HHs facing cat. Payments
Sun  et al. [30] Rural China;
Shandong Province.
Total health care
costs.
Cat. (R) HH-survey. - 40% of income minus
average food exp.; with
sensitivity analysis of
20%-30%-50%-60%
Cat. payments decreased by 34.77% between 20% and 60%
thresholds
Su  et al. [35] Burkina Faso Total healthcare
costs
Cat. (R) Cat. payments decreased by 57.26% between 20% and 60%
thresholds
Niëns  et al. [16] Indonesia and India affordability
glibenclamide
(anti-diabetic)
Cat. (P) HH- surveys 5% threshold of daily
income
65.9% of Indonesian & 78.6% of Indian pop. face Cat.
payment
Cameron et al. [3] 36 countries Medicine
affordability
LPGW (P) N/A N/A affordability differs much in WHO-regions
Abbreviations: Cat, catastrophic; cons, consumption; exp, expenditure; FPL, food-poverty line; HC, health care; HH, Household; Impov, Impoverishment; LPGW, Lowest Paid Government Worker; N/A, not
applicable; OOP, out-of-pocket; PL, poverty line; poppopulation; UC, universal coverage; (P), prospective; (R), Retrospective.
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Table 2
Affordability estimates: impact of methods and thresholds.
Methods Outcome measure Medicine (condition)
Glibenclamide (diabetes) Amoxicillin (acute
respiratory infection)
Atenolol
(hypertension)
Panel A: Affordability estimates for 3 lowest priced generic medicines with micro data and methods
Impoverishment impoverishment rate
<US$1.25 poverty line
5.8% 14.2% 21.6%
impoverishment rate
<US$2.00 poverty line
3.7% 8.2% 11.6%
Catastrophic
payment
Catastrophic expenditure
at  5%
65.9% 95.8% 98.6%
Lowest  paid
government worker
# of daily wages needed 0.6 days 0.4 days 2.4 days
Panel  B: impoverishment rates at different thresholds
2011 National PL Indonesia
(US$0.89)
4.7% 13.5% 22.5%
US$1.08 6.0% 15.2% 23.5%
US$2.15 2.8% 6.3% 9.3%
Panel  C: catastrophic payments at different thresholds
1.0% >99% >99% >99%
2.5%  92.3% >99% >99%
5.0%  65.9% 95.8% 98.6%
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10.0% 17.2%
t risk of facing catastrophic payments [16]. Wagstaff and
an Doorslaer retrospectively used a range of thresholds
2.5%, 5%, 10% and 15%) which were applied for both pre-
ayment income and non-food expenditures [26]. One of
heir ﬁndings was that, in Vietnam, it was not inpatient care
hat increased poverty so much, but rather expenditures
elated to non-hospital care like medicine procurements.
naul et al. also applied the catastrophic spending method
ut did so using a 30% threshold of income. Whereas they
ound almost all households with impoverishing effects
o be from the poorest quintile, catastrophic health care
ayments were observed throughout the income distri-
ution [34]. In Thailand, whereas Limwattananon et al.
pplied a threshold of 10% of total consumption includ-
ng expenditures on food [31] Somkotra and Lagrada used
anges of thresholds of both total consumption (5%, 10% and
5%) and non-food consumption (20%, 25% and 30%) [29].
oth studies reported that moving toward implementation
f universal health insurance coverage in 2001 decreased
atastrophic expenditures [29,31]. The previous overview
hows the affordability of health care and medicines in
MICs to vary and highlights the different thresholds used
etween but also within methods. Whereas some of these
ifferences are likely to be data driven others may  reﬂect
ifferences in approach to or (even) opinion about afford-
bility.
Using the LPGW methodology Cameron et al. ﬁnd
edicine affordability to differ signiﬁcantly between
HO-regions. They show whereas treating an ulcer with
 month’s course of private sector originator brand (OB)
anitidine (150 mg  capsules or tablets, two a day for 30
ays) costs more than 35 days’ wages in Africa, in South-
ast Asia this is just 2.7 days’ wages [3]. Moreover, when
eﬁning affordability in relation to some normative thresh-
ld in terms of a maximum number of wage days a person
ould spend on a purchase of medicines before deeming
t unaffordable, similar problems regarding comparability88.1% 96.4%
78.0% 92.5%
between studies could occur as for the two other methods
described above. These results are summarized in Table 1.
We will show that the previously explained differences
and choices are not only theoretical but in effect inﬂuence
outcomes. To illustrate this, and to stimulate the debate
regarding appropriate and comparable measurement of
affordability, we prospectively calculate the affordability
of Lowest Priced Generic (LPG) glibenclamide, amoxicillin
and atenolol in Indonesia, using both the impoverishment
and catastrophic spending methods.
5. Putting the methods into practice: the case of
medicine affordability in Indonesia
Niëns et al. [16] used LPG prices to prospectively
calculate the affordability of LPG glibenclamide (used for
treating diabetes; 5 mg  per tablet at a daily cost of US$0.11)
in Indonesia. They applied the impoverishment method
as described by O’Donnell et al. [36], using household
level income data from the 2005 wave of the Indone-
sian National Socioeconomic Survey (Susenas – n = 7302
households) [37]. Thus, they calculated the percentage of
the population that would be pushed below a poverty line
when having to procure LPG glibenclamide. Using PLs of
US$1.25 and US$2.00 they found 28.8% and 61.7% of the
population, respectively, to already live below the poverty
line before hypothetical medicine purchases. For them, the
medicines may  therefore be deemed unaffordable at any
price above zero.
Applying the impoverishment method prospectively
indicated that 5.8% and 3.7% of the population would be
impoverished due to medicine procurement, using the two
respective poverty lines [16]. Working with the prospective
catastrophic payment method and a threshold of 5% (using
household level income data), indicated that a proportion
of 65.9% of the population would not be able to purchase
glibenclamide without a catastrophic payment exceeding
 / Health50 L.M. Niëns, W.B.F. Brouwer
5% of their daily income [16]. Using the LPGW approach
WHO/HAI ﬁnds the LPGW needs 0.6 days’ wages to pay for
one course of treatment.
Here we repeated the same calculations for gliben-
clamide, amoxicillin (used for treating an acute respiratory
infection; 250 mg  per tablet at a daily cost of US$0.27) and
atenolol (against hypertension; 50 mg  per tablet at a daily
cost of US$0.43) (see Table 2: panel A).
Besides the US$1.25 and US$2.00 poverty lines, we
used the same household level income data to calculate
the impoverishment and catastrophic payment rates for
these three medicines at different thresholds. Impoverish-
ment rates were calculated for the US$1.08 and US$2.15
poverty lines as used by van Doorslaer et al. [2] and the
2011 national poverty line of Indonesia which is US$0.89
[38]. All calculations were done with poverty lines that
were recalculated to local currency units using the Pur-
chasing Power Parity conversion factor from 2005 [39].
Panel B shows the impoverishment rates to vary strongly
with the thresholds used. Whereas for glibenclamide we
ﬁnd 4.7% of the Indonesian population impoverished at the
national poverty line, for the US$1.08 and US$2.15 poverty
lines this is 6.0% and 2.8% respectively. For amoxicillin and
atenolol these proportions range from 15.2% and 23.5% at
the US$1.08 poverty line to 6.3% and 9.3% at the US$2.15
poverty line, with the impoverishment rates at Indonesia’s
national poverty line, i.e. 13.5% for amoxicillin and 22.5%
for atenolol falling in between.
Varying the catastrophic payment thresholds we  also
ﬁnd large differences (see Panel C). If people are allowed to
spend no more than 1.0% of their daily income on gliben-
clamide this medicine is unaffordable for more than 99% of
the population, whereas increasing the threshold to 10%
results in glibenclamide being deemed unaffordable for
17.2% of the population. For amoxicillin and atenolol these
proportions range from over 99% for the 1% threshold to
78% and 92.5% at the 10% threshold, respectively.
6. Conclusion and discussion
Affordability is an important issue in many health care
systems, especially those in LMICs. Van Doorslaer [2] high-
light that only in Asia, already 78 million people would be
pushed below the poverty line of $1 per day after paying for
health care. Medicines commonly constitute a large part of
health care consumption. In many LMICs, therefore, essen-
tial medicines are unaffordable for many [3,7]. Niëns et al.,
for example, estimated that for over two-ﬁfths of the in
total approximately 775 million people in 16 LMICs, essen-
tial medicines are unaffordable [7]. They show this problem
to be especially pressing for people suffering from chronic
non-communicable diseases which require life-long ongo-
ing medicine purchases [7].
These ﬁgures demonstrate that improving the afford-
ability of health care, and especially medicines, should be
an important policy goal. The current levels of unafford-
ability can have important detrimental health effects in the
most vulnerable groups in the world. Governments have
several options at their disposal to increase the affordabil-
ity of health care and medicines, also in LMICs. From ensur-
ing that quality assured generic medicines are available in Policy 112 (2013) 45– 52
the public sector, to removing import levies on medicines
and exempting them from value added tax, to implement-
ing regulated (regressive) mark-up systems for medicines
in the distribution chain [3]. Furthermore, installing pre-
payment schemes (insurance) to ﬁnance health care offers
the possibility for governments to better control (generic)
medicine purchases and prices [40–42]. Such policies are
ideally based on sound information on the current prob-
lem and evaluated to judge their impact. In that context it
is pivotal to measure and quantify affordability.
Over the years, useful methodology has been devel-
oped by leading experts in the ﬁeld [e.g. 25,36] that allows
the quantiﬁcation of the inherently ‘vague’ concept of
affordability. Still, as the literature and our results show,
the impact of the methods chosen to measure affordability
as well as the thresholds chosen within those methods is
signiﬁcant on ﬁnal outcomes. It appears that the observed
differences, which are also reﬂected in the empirical
literature regarding affordability, reﬂect the difﬁculty of
univocally grasping the concept of affordability and to ﬁnd
suitable and general thresholds for affordability. The two
most prominent methods, the impoverishment and the
catastrophic payment method, both use different opera-
tionalisations of the concept of affordability and within
the methods different thresholds are used, reﬂecting the
difﬁculty in setting one unique standard for affordability.
While the difﬁculty is understandable, the implications
are worrisome since arbitrary variations in thresholds
may  strongly affect affordability estimates and, hence,
may–unduly if the thresholds or methods may  be deemed
inappropriate–inﬂuence policy makers and the sense of
urgency regarding matters of ﬁnancial access to health
care and medicines.
In light of these ﬁndings, we argue that two  things
would be useful. First, it may  be worthwhile to create
a (preliminary) standard for calculating affordability.
Rather than attempting to develop new methods (with
own  limitations) a fruitful way  forward is to work with a
ﬁxed combination of methods and a ﬁxed combination of
affordability thresholds. As a ﬁrst suggestion, we  would
recommend using both the impoverishment and cata-
strophic payment methods. This would ensure that large
proportions of income being spent or required for the pur-
chase of medicines would be detected (even when these
do not push the individuals involved into poverty) and
that those individuals who are pushed into poverty would
also be detected; even when the proportion of income
spent on medicines is fairly limited. Second, in terms of a
threshold, it seems that a general discussion between pol-
icy makers and researchers leading to a (standard) range
of thresholds would be a logical choice, given the current
variation.
We emphasize that the threshold can and should be
set in relation to the good or service under study. For
instance, since medicines form only a portion of total health
care expenditures, one may  set catastrophic payments
thresholds and impoverishment thresholds higher/lower
when studying medicine expenditures than when studying
health care expenditures. Studying partial expenditures in
some area should be judged against different thresholds
then when considering the whole. Similarly, a distinction
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ould be made between chronic and acute diseases, as the
ormer require ongoing, sometimes lifelong expenditures.
hese may, ceteris paribus, sooner be considered unaf-
ordable than once only purchases. For instance, in case of
hronic conditions, it is less possible for people to use cop-
ng mechanisms like spending savings, loaning or selling
ssets to pay for the health care expenditures [8].
To help politicians and governments improve the access
o medicines we therefore argue scholars and policy
akers should discuss and agree on an international
enchmark for how to best address the affordability ques-
ion. An international benchmark, both in calculating and
eporting, would foster transparency and intertemporal
nd international comparison. Since comparison in itself
an increase the awareness and sense of urgency for gov-
rnments to act swiftly on these issues, such a benchmark
hould be discussed.
To conclude, affordability is important and increasingly
uantiﬁed. In order to increase comparability, also across
ountries, we urge for a further standardization of the mea-
urement of affordability.
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